The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.40
Bid: 2.32
Ask: 2.54
Change: 0.04 (1.67%)
Spread: 0.22 (9.483%)
Open: 2.41
High: 2.41
Low: 2.34
Prev. Close: 2.39
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Dealings

23 Jul 2009 16:17

RNS Number : 2020W
Immupharma PLC
23 July 2009
 



For Immediate Release

23 July 2009

ImmuPharma PLC

Directors' Dealings

Institutions increase stake

 

ImmuPharma PLC ('ImmuPharma' or the 'Company') (LSE:IMM) announces that a number of existing and new blue-chip institutional investors have purchased shares from Richard Warr and the Trusts of Richard Warr and Dimitri Dimitriou, who are two of ImmuPharma's founders and Directors.  A total of 12.5 million ordinary shares (16.1% of the issued share capital) of 10 pence each in the Company, were placed by Noble & Company Limited at a price of 86 pence per share to institutional investors on 23 July 2009. Panmure Gordon is the NOMAD and Corporate Broker to the Company. 

 

Following the disposal, the current holdings directly or through Trust are:

Ordinary Shares Sold

Ordinary Shares Retained

Percentage  of shares in issue

Richard Warr (1)

6,250,000

3,528,968

4.6%

Dimitri Dimitriou (2)

6,250,000

3,528,969

4.6%

Dr Zimmer & Family

0

23,056,602

29.8%

 

(1)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Warr family has a beneficial interest and shares held directly by Richard Warr

 

(2)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Dimitriou family has a beneficial interest. 

 

Richard Warr, ImmuPharma's Chairman said: "We are delighted with the support received from our existing investors and the demand from new investors including M&G Investments.  The allocation of these shares further increases ImmuPharma's free float with the aim of improving overall liquidity."

 

For further information please contact: 

ImmuPharma PLC

+44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer 

Richard Warr, Chairman

Panmure Gordon

+44 151 243 0963

Andrew Burnett/ Rakesh Sharma 

Noble & Company Limited

+44 20 7763 2335

John Millar

Buchanan Communications

+44 20 7466 5000

Lisa Baderoon 

Rebecca Skye Dietrich

More information on the Company can be found at www.immupharma.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSELFIDSUSEFW
Date   Source Headline
11th Apr 20147:00 amRNSImmuPharma Sponsors the 2014 European Lupus Confer
14th Oct 20137:00 amRNSAdditional Listing
27th Sep 20137:00 amRNSHalf Yearly Report
13th Aug 20137:00 amRNSUPDATE CANCER PROGRAMME IPP-204106
31st Jul 20137:00 amRNSFDA GRANTS IMMUPHARMA AMENDED SPA
8th Jul 20138:00 amRNSIMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
5th Jun 20137:00 amRNSHolding(s) in Company
23rd May 201312:29 pmRNSResult of AGM
21st May 20137:00 amRNS£50M Financing Facility - Darwin Strategic
22nd Apr 20137:00 amRNSPosting of Annual Report and AGM Notice
9th Apr 20137:00 amRNSPreliminary Results
28th Feb 20137:01 amRNSImmuPharma Commences Trading on Stuttgart Exchange
28th Jan 20134:03 pmRNSDirector/PDMR Shareholding - Replacement
28th Jan 20131:18 pmRNSDirector/PDMR Shareholding
28th Jan 20139:33 amRNSCNRS Confirms Lupuzor's (TM) Effectiveness
15th Nov 20127:30 amRNSLupuzor Presentation
5th Nov 20127:00 amRNSLupuzor Presentation
3rd Oct 20127:00 amRNSNotification of Major Interest in Shares
26th Sep 20127:01 amRNSFirst Cancer Patients in New Trial Begin Dosing
26th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSNotification of Interim Results
7th Sep 201211:12 amRNSRodman and Renshaw Conference
17th Aug 20129:11 amRNSNotification of Major Interest in Shares
11th Jul 20127:00 amRNSVoted Best Medical Research & Development Company
9th Jul 20127:00 amRNSNew Corporate Website
3rd Jul 20127:00 amRNSAppointment of Joint Broker
23rd May 201212:20 pmRNSAnnual General Meeting: 2012
17th Apr 20127:00 amRNSPosting of Annual Report and AGM Notice
27th Mar 20127:00 amRNSPreliminary Results
29th Feb 20127:00 amRNSAppoints Head of Investor Relations
24th Jan 201212:44 pmRNSDirector's Dealings
3rd Nov 20117:00 amRNSLupuzorT granted approval to start phase III
1st Nov 201110:23 amRNSNotification of Major Interest in Shares
1st Nov 201110:18 amRNSNotification of Major Interest in Shares
21st Oct 20117:00 amRNSImmuPharma regains Lupuzor rights
30th Sep 20117:00 amRNSINTERIM RESULTS ANNOUNCEMENT
23rd Sep 20119:34 amRNSNotification of Interim Results
12th Jul 20112:47 pmRNSNotification of Major Interest in Shares
19th May 201111:19 amRNSResult of Annual General Meeting
5th May 20117:00 amRNSIPP-204106 paper published
26th Apr 20114:38 pmRNSAnnual Report and Accounts & Notice of AGM
5th Apr 20117:00 amRNSPreliminary Results
30th Mar 20117:00 amRNSNotification of Preliminary Results
21st Feb 20117:00 amRNSUpdate on progress of Phase I/IIa Clinical Trial
19th Oct 20101:08 pmRNSUpdate on Phase IIa Clinical Trial
11th Oct 20102:30 pmRNSNotification of major interests in shares
11th Oct 20102:30 pmRNSAdditional Listing and Total Voting Rights
30th Sep 20107:00 amRNSInterim Results
28th Sep 201010:18 amRNSNotification of Interim Results
28th Jun 20107:00 amRNSPresentation at the International Congress

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.